Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor α-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect

Molecular Pharmacology

Volumn 66, Issue 4, 2004, Pages 864-869

  Rao, Balaji M ^a   Driver, Ian ^a   Lauffenburger, Douglas A ^b   Wittrup, K Dane ^b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ALPHA CHAIN; ARTICLE; BIOASSAY; CELL PROLIFERATION; CELL SURFACE; IN VIVO STUDY; MATHEMATICAL MODEL; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR AFFINITY; T LYMPHOCYTE;

EID: 4844219871     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.4.864     Document Type: Article

References (18)

1. Arima N, Kamio M, Imada K, Hori T, Hattori T, Tsudo M, Okuma M, and Uchiyama T (1992) Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling. J Exp Med 176:1265-1272.
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116.
3. Dubois S, Mariner J, Waldmann TA, and Tagaya Y (2002) IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity 17:537-547.
4. Fallon EM and Lauffenburger DA (2000) Computational model for effects of ligand/receptor binding properties on interleukin-2 trafficking dynamics and T cell proliferation response. Biotechnol Prog 16:905-916.
5. Fehniger TA, Cooper MA, and Caligiuri MA (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13:169-183.
6. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, and Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696.
7. Guthridge MA, Stomski FC, Thomas D, Woodcock JM, Bagley CJ, Berndt MC, and Lopez AF (1998) Mechanism of activation of the GM-CSF, IL-3 and IL-5 family of receptors. Stem Cells 16:301-313.
8. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
9. Hemar A and Dautry-Varsat A (1990) Cyclosporin A inhibits the interleukin 2 receptor alpha chain gene transcription but not its cell surface expression: the alpha chain stability can explain this discrepancy. Eur J Immunol 20:2629-2635.
10. Hodge S, Hodge G, Flower R, and Han P (2000) Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand J Immunol 51:67-72.
11. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, Kita K, and Uchino H (1987) Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 70:1069-1072.
12. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, and Bradley EC (1990) Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 50:2009-2017.
13. Liparoto SF, Myszka DG, Wu Z, Goldstein B, Laue TM, and Ciardelli TL (2002) Analysis of the role of the interleukin-2 receptor gamma chain in ligand binding. Biochemistry 41:2543-2551.
14. Nelson BH and Willerford DM (1998) Biology of the interleukin-2 receptor. Adv Immunol 70:1-81.
15. Rao BM, Girvin AT, Ciardelli T, Lauffenburger DA, and Wittrup KD (2003) Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng 16:1081-1087.
16. Smith KA (1989) The interleukin 2 receptor. Annu Rev Cell Biol 5:397-425.
17. Storek J, Dawson MA, and Maloney DG (2000) Normal T, B and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 95:2993-2994.
18. Theze J, Alzari PM, and Bertoglio J (1996) Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 17:481-486.